EIB funds Ebola vaccine development

Published: 20-Jan-2015
Research & Development Infection Control

Lends Bavarian Nordic €50m to accelerate Ebola project


The European Investment Bank (EIB) is lending €50m to Denmark-based biotechnology company Bavarian Nordic to accelerate its work in developing a vaccine against the Ebola virus. The decision showed that the bank backed 'investment where it is needed…in difficult or uncertain circumstances', claimed EIB President Werner Hoyer. The company started Phase 1 clinical trials this month.

See more

You may also like

Research & Development

EIB supports Bavarian Nordic’s development of Ebola and cancer vaccines

Read more
Prostvac is the company's leading targeted immunotherapy candidate

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Using clinical data to drive effective formulation optimisation Conventional approaches to develop and optimise formulations are suboptimal and require extensive pharmaceutical development activities to be undertaken prior to clinical evaluation and performance validation
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Bringing CAR-T therapy within reach: how decentralised manufacturing will improve patient access By offering a lifeline to patients with otherwise untreatable conditions, CAR-T cell therapy has transformed cancer treatment. Yet, despite the breakthrough potential of these patient-specific therapies, access remains severely limited
  3. Capricorn Scientific and florabio join forces to supply animal-free vaccine solutions Strategic partnership will accelerate innovation from lab to GMP scale with high-yield solutions for scalable production
  4. Pfizer discontinues development of GLP-1 receptor agonist, danuglipron The oral GLP-1 receptor agonist was discontinued due to reports of potential drug-induced liver toxicity in one patient during phase III trials
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    PROTACs: current landscape and their significance in drug discovery PROteolysis TArgeting Chimeras (PROTACs) represent a revolutionary approach to drug discovery that leverages their chemically induced proximity to degrade disease-causing proteins using the cellular ubiquitin-proteasome system

Upcoming event

Making Pharmaceuticals

29-30 April 2025 | Conference | Coventry, UK See all

You may also like

Research & Development

EIB supports Bavarian Nordic’s development of Ebola and cancer vaccines

Prostvac is the company's leading targeted immunotherapy candidate
Sustainability

Cut Argon use and costs with Shimadzu’s ICPMS-2040/2050

New Mini-Torch System offers precision analysis with 40% less Argon
Research & Development

Roche to put $50bn into US manufacturing and R&D footprint

The company will build new gene therapy, weight loss medication and continuous glucose monitoring manufacturing facilities situated across the US, as well as dedicated R&D centres
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Bringing CAR-T therapy within reach: how decentralised manufacturing will improve patient access

By offering a lifeline to patients with otherwise untreatable conditions, CAR-T cell therapy has transformed cancer treatment. Yet, despite the breakthrough potential of these patient-specific therapies, access remains severely limited
Research & Development

Capricorn Scientific and florabio join forces to supply animal-free vaccine solutions

Strategic partnership will accelerate innovation from lab to GMP scale with high-yield solutions for scalable production
Manufacturing

Beyond performance: GF’s SYGEF turns 50

PVDF piping systems continue to provide trusted solutions for demanding industries
Manufacturing

Titan Enterprises powers forward with green initiatives

Strategic investments in solar, supply chain and recycling drive sustainability
Subscribe now